Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 14,134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: YJ001 for Spray Use, Placebo of YJ001 for Spray Use; Drug
Lead sponsor: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Fredericksburg, Texas

Conditions: Neck Pain
Interventions: Cervigard Neck Collar; Device
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more

Conditions: Migraine
Interventions: Treximet, Placebo; Drug
Lead sponsor: Premiere Research Institute; Other
Eligibility: 12 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more

Conditions: Patient Engagement, Patient Empowerment, Patient Activation
Interventions: Patient partnership tools; Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 50 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Fort Worth, Texas

Conditions: Prostatic Neoplasms
Interventions: VT-122, Placebo; Drug
Lead sponsor: Vicus Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more

Conditions: Systemic Lupus Erythematosus
Interventions: SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 22
States / cities: Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more

Conditions: Diphtheria, Pertussis, Tetanus
Interventions: Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Durham, North Carolina • Houston, Texas • Seattle, Washington

Conditions: Advanced Solid Tumor
Interventions: OMTX705, Pembrolizumab, Tislelizumab (BGB-A317); Drug
Lead sponsor: Oncomatryx Biopharma S.L.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Refractory Chronic Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 55
States / cities: Peoria, Arizona • Little Rock, Arkansas • Los Angeles, California + 51 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 34
States / cities: Colorado Springs, Colorado • Kissimmee, Florida • Miami, Florida + 26 more

Conditions: Asthma
Interventions: Placebo, R940343 1mg, R940343 2mg; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 51
States / cities: Fullerton, California • Los Angeles, California • Mission Viejo, California + 43 more

Conditions: Healthy Male
Interventions: GCC-4401, GCC-4401C; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Negative Symptoms of Schizophrenia
Interventions: Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg; Drug
Lead sponsor: Minerva Neurosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more

Conditions: Surgery, Surgery--Complications, Perioperative/Postoperative Complications
Interventions: Anesthesia Control Tower monitoring; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 79,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type2 Diabetes Mellitus
Interventions: Faith-Based (FB, BHT DSMS), Faith-Placed (FP, Stanford DSMP); Behavioral · Other
Lead sponsor: The University of Texas at San Antonio; Other
Eligibility: 21 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain
Interventions: SRP-3D (diethylamide), Placebo; Drug
Lead sponsor: South Rampart Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neuropathic Corneal Pain
Interventions: Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution; Drug · Other
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lupus Erythematosus, Systemic
Interventions: Atorvastatin, Placebo atorvastatin; Drug
Lead sponsor: Laura Schanberg; Other
Eligibility: 10 Years to 21 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1
Interventions: ABBV-181, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 11 more

Conditions: Dermatitis, Atopic, Eczema
Interventions: Desonide Cream, Amino Acid Moisturizing Cream; Drug · Other
Lead sponsor: NeoStrata Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Serious Gram-negative Infections
Interventions: Intravenous infusions of WCK 5222, Placebo; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Congenital Adrenal Hyperplasia
Interventions: Tildacerfont/Placebo; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: URG101, Placebo, Lidocaine, Heparin; Drug
Lead sponsor: Urigen; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Escondido, California • San Diego, California • Cartersville, Georgia + 8 more

Search by objective public record fields.

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

A Novel Device for Neck Pain in Active-duty Military Personnel With Forward Head Posture.

Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

Treximet Early Intervention Adolescent Migraine

Partnership in Resilience for Medication Safety (PROMIS)

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Pertussis Vaccine in Healthy Pregnant Women

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety

Building a Healthy Temple: a Diabetes Self-management Support Program in Hispanic Faith Community Settings

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome